

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

MFE-296

RRID:CVCL_1406

Type: Cell Line

Proper Citation

RRID:CVCL_1406

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1406

Proper Citation: RRID:CVCL_1406

Description: Cell line MFE-296 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Endometrial adenocarcinoma

Defining Citation: [PMID:8150529](#), [PMID:9620227](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MFE-296

Synonyms: MFE 296, MFE296

Cross References: CLO:CLO_0007693, CLDB:cl5081, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:942, BioSample:SAMN03473590, BioSample:SAMN10987797, cancercellines:CVCL_1406, Cell_Model_Passport:SIDM00334, ChEMBL-Cells:ChEMBL3308374, ChEMBL-Targets:ChEMBL1075503, Cosmic:908130, Cosmic:1105621, Cosmic:1177684, Cosmic:1434195, Cosmic:1576463, Cosmic:2030479, Cosmic-CLP:908130, DepMap:ACH-000879, DSMZ:ACC-419, DSMZCellDive:ACC-419,

ECACC:98031101, EGA:EGAS00001000978, GDSC:908130, GEO:GSM374975, GEO:GSM375434, GEO:GSM844604, GEO:GSM844605, GEO:GSM887312, GEO:GSM888388, GEO:GSM1670099, IARC_TP53:21496, LiGeA:CCL_405, LINCS_LDP:LCL-1501, PharmacDB:MFE296_920_2019, PRIDE:PXD030304, Progenetix:CVCL_1406, PubChem_Cell_line:CVCL_1406, Wikidata:Q54905382

ID: CVCL_1406

Record Creation Time: 20220427T220804+0000

Record Last Update: 20260913T004851+0000

Ratings and Alerts

No rating or validation information has been found for MFE-296.

No alerts have been found for MFE-296.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. *Molecular cancer therapeutics*.

Pham BQ, et al. (2025) mTORC1 regulates the pyrimidine salvage pathway by controlling UCK2 turnover via the CTLH-WDR26 E3 ligase. *Cell reports*, 44(1), 115179.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Yi SA, et al. (2024) mTORC1-CTLH E3 ligase regulates the degradation of HMG-CoA synthase 1 through the Pro/N-degron pathway. *Molecular cell*, 84(11), 2166.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.

Zhang W, et al. (2023) HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. *Cell reports*, 42(11), 113352.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.